טוען...
Valproate augments Niraparib killing of tumor cells
PARP1 inhibitors are approved therapeutic agents in ovarian carcinomas, and have clinical activity in some breast cancers. As a single agent, niraparib killed ovarian and mammary tumor cells via an ATM-AMPK-ULK1 pathway which resulted in mTOR inactivation and the formation of autophagosomes, tempora...
שמור ב:
| הוצא לאור ב: | Cancer Biol Ther |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Taylor & Francis
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6154859/ https://ncbi.nlm.nih.gov/pubmed/29923797 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2018.1472190 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|